8-K: CG Oncology Q3 2025: BLA Submission, Strong Cash

CG Oncology reports Q3 2025 financial results, initiates BLA submission for cretostimogene, and maintains strong cash position.

Summary

• Initiated rolling Biologics License Application (BLA) submission to the U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
• Demonstrated a 24-month complete response (CR) rate of 41.8% for cretostimogene monotherapy in BOND-003 Cohort C, observed in 46 out of 110 patients.
• Completed enrollment of PIVOT-006, a Phase 3 study in intermediate risk (IR) NMIBC, approximately 10 months ahead of schedule.
• Cash, cash equivalents, and marketable securities totaled $680.3 million as of September 30, 2025, sufficient to fund operations into the first half of 2028.
• Net loss for the three months ended September 30, 2025, was $43.8 million, or ($0.57) per share, compared to a net loss of $20.4 million, or ($0.30) per share, for the same period in 2024.
• Research and Development (R&D) expenses increased to $27.9 million in Q3 2025 from $19.6 million in Q3 2024.
• General and Administrative (G&A) expenses increased to $23.3 million in Q3 2025 from $8.7 million in Q3 2024.

Sentiment

Score: 8

Explanation: The filing presents strong clinical progress with the initiation of a BLA submission and robust durability data for cretostimogene. The early completion of PIVOT-006 enrollment and a solid cash runway into 2028 are significant positives. While net losses increased, this is expected for a company in late-stage clinical development and regulatory preparation. The overall tone is highly positive regarding product development and financial stability.

Positives

• Initiated rolling BLA submission for cretostimogene monotherapy in HR BCG-unresponsive NMIBC, a significant regulatory milestone.
• Cretostimogene has both Fast Track and Breakthrough Therapy Designations, which are intended to accelerate the path to U.S. FDA submission.
• BOND-003 Cohort C data showed a robust 24-month complete response landmark rate of 41.8% for cretostimogene monotherapy, with 90% of 12-month responders remaining disease-free at 24 months, reaffirming best-in-disease durability.
• The safety profile of cretostimogene remained consistent with no Grade 3 or greater treatment-related adverse events or deaths reported in BOND-003 Cohort C.
• Completed enrollment of the PIVOT-006 clinical trial (IR NMIBC Phase 3 study) approximately 10 months ahead of schedule, underscoring strong patient and physician interest.
• Maintained a strong cash position with $680.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Existing cash, cash equivalents, and marketable securities are expected to be sufficient to fund operations into the first half of 2028.
• Successfully raised approximately $48.7 million from the sale of 1,515,151 shares through an at-the-market (ATM) facility based on reverse inquiry from an existing, high-quality fund.

Negatives

• Net loss significantly increased to $43.8 million in Q3 2025 from $20.4 million in Q3 2024.
• Net loss per share increased to ($0.57) in Q3 2025 from ($0.30) in Q3 2024.
• Research and Development (R&D) expenses increased by 42.3% to $27.9 million in Q3 2025, primarily due to increased clinical trial expenses and headcount.
• General and Administrative (G&A) expenses increased by 167% to $23.3 million in Q3 2025, primarily attributed to increased legal expenses, other professional fees, and personnel-related expenses.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data becomes available.
• Potential delays in the commencement, enrollment, and completion of clinical trials, including the BOND-003 and PIVOT-006 trials.
• Capital resources may be used sooner than expected and may be insufficient to allow the achievement of anticipated milestones.
• Dependence on third parties in connection with manufacturing, shipping, and clinical and preclinical testing.
• Results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization.

Future Outlook

The company anticipates completing its rolling BLA submission for cretostimogene in HR BCG-unresponsive NMIBC in 2026. It expects to share topline data from BOND-003 Cohort P and first results from CORE-008 Cohort A before year-end 2025, and topline data from CORE-008 Cohort CX in the first half of 2026. Existing cash, cash equivalents, and marketable securities are projected to fund operations into the first half of 2028.

Management Comments

• "I am proud of the meaningful progress we have made over the last few months, most notably, the initiation of our BLA submission of cretostimogene for our lead indication of HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease." Arthur Kuan, Chairman & Chief Executive Officer.
• "With cretostimogenes unique profile, we remain committed to advancing a robust clinical, regulatory, and technical strategy designed to support an optimized label and expansion into additional indicationspositioning cretostimogene as a potential backbone therapy for a broad range of NMIBC patients." Arthur Kuan, Chairman & Chief Executive Officer.
• "We look forward to sharing additional data from BOND-003 Cohort P and CORE-008 Cohort A before year-end." Arthur Kuan, Chairman & Chief Executive Officer.

Industry Context

The company is a late-stage clinical biopharmaceutical company focused on developing a potential bladder-sparing therapeutic for patients with bladder cancer, an area with significant unmet medical need, particularly for those unresponsive to Bacillus Calmette Guerin (BCG) therapy. The accelerated enrollment in PIVOT-006 and the initiation of the BLA submission highlight the urgency and potential market for effective NMIBC treatments. Cretostimogene's reported "best-in-disease durability" positions it as a strong contender in the NMIBC therapeutic landscape, aiming to provide a backbone therapy for a broad range of patients.

Comparison to Industry Standards

• Cretostimogene's 24-month complete response rate of 41.8% and 90% durability for 12-month responders in BOND-003 Cohort C is described as "best-in-disease durability and tolerability" for HR BCG-unresponsive NMIBC, implying a favorable comparison to existing or developing therapies in this specific indication.
• PIVOT-006 is noted as "one of the largest randomized Phase 3 studies in this patient population and encompasses the broadest range of patient types per AUA/SUO guidelines," suggesting a comprehensive approach compared to other trials in intermediate-risk NMIBC.

Stakeholder Impact

• Shareholders: Potential for increased value due to significant clinical progress, BLA submission, and extended cash runway. Increased net loss is a typical short-term characteristic for a development-stage biotech.
• Patients with NMIBC: Potential for a new, effective bladder-sparing therapeutic option, especially for those unresponsive to BCG, offering enhanced quality of life.
• Employees: Increased headcount mentioned in G&A and R&D expenses suggests company growth and stable employment prospects.
• Regulatory Authorities (FDA): Active engagement through BLA submission and Fast Track/Breakthrough Therapy Designations, indicating a structured path towards market approval.

Next Steps

• Share topline data from BOND-003 Cohort P (HR BCG-unresponsive NMIBC in Ta/T1 disease without CIS) in Q4 2025.
• Share first results from CORE-008 Cohort A (HR BCG-naive NMIBC with CIS +/Ta/T1) in Q4 2025.
• Share topline data from CORE-008 Cohort CX (HR BCG-exposed NMIBC, combination of cretostimogene with gemcitabine) in 1H 2026.
• Complete BLA submission in the initial indication (HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease) in 2026.

Key Dates

Recommendation

The initiation of a rolling BLA submission for cretostimogene, coupled with robust 24-month complete response rates and durability data in a high-need indication (HR BCG-unresponsive NMIBC), represents a major de-risking event and a clear path towards commercialization. The early completion of enrollment for a large Phase 3 trial (PIVOT-006) underscores strong market interest. While the company reported increased net losses, this is a natural and expected consequence of advancing multiple late-stage clinical programs and preparing for regulatory filings, which are critical investments for future revenue generation. The strong cash position, extended runway into 2028, and recent capital raise from a "high-quality fund" further bolster financial stability. These factors collectively indicate strong operational execution, significant pipeline progress, and a favorable outlook, making it a compelling "strong buy" for investors.

Keywords

CG Oncology, CGON, cretostimogene, bladder cancer, NMIBC, BCG-unresponsive, BLA submission, FDA, clinical trials, oncology, biopharmaceutical, financial results, Q3 2025, BOND-003, PIVOT-006, CORE-008, oncolytic immunotherapy